imtoken官方网站|gdtc

作者: imtoken官方网站
2024-03-13 05:03:20

GADTC_Student_Portal

GADTC_Student_Portal

Student Portal

Sign in to start your session

Remember Me

Sign In

Forgot Password?

Faculty Evaluation

marketwatch.com

etwatch.comPlease enable JS and disable any ad blocker

广东省金银珠宝检测中心有限公司

广东省金银珠宝检测中心有限公司

广东省金银珠宝检测中心欢迎您!

· 关于我们· 联系我们

标题

简介

内容

作者

搜索全部

广东省金银珠宝检测中心

首页

单位介绍

中心介绍

公正性声明

专家团队

业务范围

服务指南

联系我们

广东省金银珠宝检测中心是经人民银行批准,并经广东省技术监督局授权的省一级首饰检测机构,通过了计量认证、审查验收和国家实验室认可的严格评审和考核。

证书查询

证书查询

证书样板

查询帮助

本系统由广东省金银珠宝检测中心提供,凡在检测中心检验过的珠宝产品,均出有鉴定证书,同时检验鉴定资料均存储在本系统中,供消费者、销售商家进行查询。

教育培训

培训中心简介

课程介绍

在线报名

培训证书查询

珠宝常识

广东省金银珠宝检测中心拥有齐全的宝石检测设备和常规鉴定仪器,丰富的实习标本,以先进的检测实验室为技术依托,立足于"国家职业标准",向全省开展珠宝首饰从业人员的职业技能培训及鉴定工作。

新闻专栏

中心动态

行业动态

培训动态

黄金贵金属行情

广东省金银珠宝检测中心新闻专栏,提供中心动态、行业动态、培训动态、黄金贵金属行情。

法规标准

检测标准

维权315

法律法规

广东省金银珠宝检测中心是经人民银行批准,并经广东省技术监督局授权的省一级首饰检测机构,通过了计量认证、审查验收和国家实验室认可的严格评审和考核。

评估专区

市场行情

精品欣赏

评宝结果

金银珠宝检测标准、消费者维权315、法律法规。

会员专区

申请注册

企业信息

电子期刊

会员风采

广东省金银珠宝检测中心会员服务专区。

学术研讨

专业性文章

期刊转载

金银珠宝学术研讨,专业性文章发布,期刊转载。

快递委托检测

专家评宝

移动端官网

证书查询 / Search

证书查询

证书编号:

总质量:

 g/ct

说明

查询时请输入证书编号和总质量,总质量为多个汉字或者"---"的,请按照证书内容输入;也可以扫描样品图片下方二维码直接显示证书信息。详情请参考证书查询帮助。

注意:证书上有两行数字编号,一个是证书编号,一个是识别码(用于中心内部管理),查询时只需输入证书编号,不要输入识别码。

最新资讯 / News

更多>>

近期中心服务器维护,部分证书查询服务受影响

客户朋友您好,我中心近期正在维护服务器,部分证书查询功能会受到影响,给您造成的不便敬请谅解。

12-20近期中心服务器维护,部分证书查询服务受影响

11-26最新招聘信息:诚聘优秀的你,加入团队

09-07关于冒用我中心名义的声明

02-12广东省金银珠宝检测中心全体员工:给大家拜年啦!

01-141月16日-17日,中心服务器维护,证书查询服务受影响

12-01一款直播热销金饰品的初步分析试验

07-217月27日- 31日 翡翠鉴定与商贸班开课通知

03-12后疫情时代奢侈品行业或许更应线上谋局

02-08广东省金银珠宝检测中心开市通知

01-31春节假期延长通知

贵金属行情 / Price

服务项目 / Service

培训报名 / Sign up

彩色宝石鉴定商贸班

钻石商贸分级班

翡翠鉴定与商贸课程班

金银珠宝饰品国家行业标准班

企业定制培训班

中心动态 / Company

更多>>

近期中心服务器维护,部分证书查询

客户朋友您好,我中心近期正在维护服务器,部分证书查询功能会受到影响,给您造成的不便敬请

12-20近期中心服务器维护,部分证书查询服务受影响

11-26最新招聘信息:诚聘优秀的你,加入团队

09-07关于冒用我中心名义的声明

02-12广东省金银珠宝检测中心全体员工:给大家拜年啦!

01-141月16日-17日,中心服务器维护,证书查询服务受影响

02-08广东省金银珠宝检测中心开市通知

培训动态 / Train

更多>>

7月27日- 31日 翡翠鉴定与商贸班

2020年受疫情影响,我们培训采取小班的方式,在这个庚子年里添加一点点温情,来加入我们的翡

07-217月27日- 31日 翡翠鉴定与商贸班开课通知

06-046月17日- 21日 翡翠鉴定与商贸班开课通知

04-185月6日 钻石分级与商贸课程班开班了

12-052018年最后一期翡翠商贸班开课,12月17日与你不见不散

07-178月20日-8月25日 钻石分级与商贸课程班暑期班开班了!!!!

04-255月21日-5月26日 钻石分级与商贸课程班,我们再约!!!

行业动态 / Industry

更多>>

后疫情时代奢侈品行业或许更应线

春节、情人节、春上新,开年本应是时尚奢品品牌的黄金档,但2020年一场突如其来的疫情,让线

03-12后疫情时代奢侈品行业或许更应线上谋局

07-17【警惕】NGTC国检发现浅淡蓝色IIb型 HPHT合成钻石

11-21何为“一物一证“?如何操作?GDTC帮你解读

11-21何为“一物一证“?如何操作?GDTC帮你解读

10-12博茨瓦纳钻石公司在SA项目中发现新的金伯利岩

06-26中国第一部合成钻石鉴定分级标准正式颁布实施

06-23海南出台两项沉香标准 规范沉香市场

珠宝常识 / Jewelry

更多>>

斯坦福大学研究人员创造一种方法

斯坦福大学研究人员创造一种方法 更快更简单地制造钻石 斯坦福大学的研究人员已经创

05-21培训报名专页

03-12斯坦福大学研究人员创造一种方法 更快更简单地制造钻石

10-12碧玺中帕拉伊巴之“蓝色魅影”

06-26原来石榴石还有这样一个奇特的品种

01-16黄色CVD合成钻石

03-16黑珍珠变白珍珠?

12-25钟情琥珀,爱我~就带我去领证吧

友情链接 / Links

中国质量技术监督局

中国工商局

广东315消费者权益网

中国珠宝玉石监督检验中心

中国宝玉石协会

广东黄金协会

华林厂商会

澳门金业同业公会

中国黄金集团公司

中国黄金网

中国白银网

中国黄金协会

广东黄金公司

上海黄金交易所

周大福珠宝

六福珠宝

周生生珠宝

钻石世家

金龙珠宝

豪柏钻石

旭荣珠宝

新浪网

优酷

爱奇艺

百度

去哪儿网

香港空间

分支机构

华林分站

番禺分站

平洲分站

东莞分站

深圳分站

四会分站

证书查询

证书查询

常见问题解答

证书样板

教育培训

培训中心简介

课程介绍

培训证书查询

珠宝常识

标准法规

检测标准

维权315

法律法规

新闻专栏

中心动态

行业动态

培训动态

贵金属动态行情

广东省金银珠宝检测中心有限公司

地址:广州市农林下路81号之3中铁大厦二楼 ( 邮政编码:510080 )

联系电话:(020) 87301500 Email:gdtest@163.com

图文传真:(020) 87303090

广东省金银珠宝检测中心 © 2015 版权所有 粤ICP备15058350号

扫一扫,关注我们

关闭

GDTC Stock Price and Chart — NASDAQ:GDTC — TradingView

GDTC Stock Price and Chart — NASDAQ:GDTC — TradingView

Search

Products

Community

Markets

News

Brokers

More

EN

Get started

Markets/USA/Stocks/Health Technology/Biotechnology/GDTCCytoMed Therapeutics LimitedGDTCNasdaq Stock MarketGDTCNasdaq Stock MarketGDTCNasdaq Stock MarketGDTCNasdaq Stock MarketMarket closedMarket closedNo tradesSee on Supercharts

Overview

Financials

News

Ideas

Technicals

Forecast

GDTC chartToday0.49%5 days−8.00%1 month−10.00%6 months−42.18%Year to date−57.76%1 year−48.25%5 years−48.25%All time−48.25%Key statsMarket capitalization‪23.87 M‬USDDividend yield (indicated)—Price to earnings Ratio (TTM)—Basic EPS (TTM)−0.28USDNet income‪−2.27 M‬USDRevenue—Shares float‪3.96 M‬Beta (1Y)1.41About CytoMed Therapeutics LimitedSectorHealth TechnologyIndustryBiotechnologyHeadquartersSingaporeWebsitecytomed.sgEmployees (FY)28Founded2018ISINSGXZ17669631FIGIBBG01BM32FR8CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. It engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.Show moreFinancialsPerformanceAnnualAnnualQuarterlyQuarterlyMoreMoreRevenue to profit conversionAnnualAnnualQuarterlyQuarterlyMoreMoreDebt level and coverageAnnualAnnualQuarterlyQuarterlyMoreMoreEarningsNext:—AnnualAnnualQuarterlyQuarterlyMoreMore‪0.00‬IdeasGDTC LongLooks like a decent trade with 2+ r/r, coming from a low base can go long after a period of accumulationLongby caveman14Updated 1See all ideas News FlowKeep readingKeep readingTechnicalsSummarizing what the indicators are suggesting.NeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyNeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyNeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyAnalyst ratingAn aggregate view of professional's ratings.NeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyNeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyNeutralSellBuyStrong sellStrong buyStrong sellSellNeutralBuyStrong buyStock brokersTradeStationFeaturedFeaturedFeaturedStocks, Futures4.4Very GoodLearn moreFrequently Asked QuestionsWhat is CytoMed Therapeutics Limited stock ticker?Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CytoMed Therapeutics Limited stocks are traded under the ticker GDTC.When is the next CytoMed Therapeutics Limited earnings date?CytoMed Therapeutics Limited is going to release the next earnings report on Feb 28, 2024. Keep track of upcoming events with our Earnings Calendar.What is CytoMed Therapeutics Limited stock price forecast for the next year?One year price forecast for CytoMed Therapeutics Limited has a max estimate of 5.00 USD and a min estimate of 5.00 USD.Does CytoMed Therapeutics Limited release reports?Yes, you can track CytoMed Therapeutics Limited financials in yearly and quarterly reports right on TradingView.How to buy CytoMed Therapeutics Limited stocks?Like other stocks, GDTC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytoMed Therapeutics Limited stock right from TradingView charts — choose your broker and connect to your account.What are CytoMed Therapeutics Limited stock highest and lowest prices ever?GDTC reached its all-time high on Jul 11, 2023 with the price of 9.25 USD, and its all-time low was 1.92 USD and was reached on Feb 7, 2024. See other stocks reaching their highest and lowest prices.

Love in every

#TradingView50M+Traders and investors use our platform.#1Top website in the world when it comes to all things investing.1.5M+Mobile reviews with 4.9 average rating. No other fintech apps are more loved.10M+Custom scripts and ideas shared by our users.BigDEUCE @FitradersRick@letstalkstocks_@bella_tradesurfer@marketcapcoin@tonys_peacetime@jonavrl02@joey_vittorelli@aliams_david_trading_gram@mytradingsetup@joey_vittorelli@udcovers@eagle_chart@isra3l_vergara@jackentrepreneur@trading.is.mylife@akamenyar@half_bake_chef@setupstradingWhatever the tradeHere's whyHere's why

English

Products

Supercharts

Pine Script™

Stock Screener

Forex Screener

Crypto Pairs Screener

Crypto Coins Screener

Stock Heatmap

Crypto Heatmap

ETF Heatmap

Economic Calendar

Earnings Calendar

Sparks

News Flow

TradingView Desktop

Mobile app

CME Group futures

Eurex futures

US stocks bundle

Company

About

Features

Pricing

Social network

Wall of Love

Athletes

Manifesto

Careers

Blog

Security vulnerability

Status page

Terms of use

Disclaimer

Privacy policy

Cookies policy

Media kit

Accessibility Statement

Community

Refer a friend

Ideas

Scripts

Streams

House rules

Moderators

Pine Script™ Wizards

Chat

For business

Widgets

Advertising

Charting libraries

Lightweight Charts™

Advanced Charts

Brokerage integration

Partner program

Education program

Select market data provided by ICE Data Services

© 2024 TradingView, Inc.

Khoa Giáo dục Thể chất

Khoa Giáo dục Thể chất

Toggle navigation

Home

TRA CỨUTHỜI KHÓA BIỂULịch học các lớpLịch sử dụng sân bãiLịch thi LỊCH TUẦNĐÀO TẠONGHIÊN CỨUTHÔNG TINDanh bạ điện thoạiHướng dẫn sinh viênHướng dẫn giảng viênTài liệu điện tửLIÊN HỆ

Trang chủ

Giới thiệu

Thông báo

Tin tức

HỆ THỐNG TỔ CHỨC

Trang chủ Giới thiệu  Giới thiệu Thông điệp của Trưởng khoa Sứ mạng - Tầm nhìn Lĩnh vực hoạt động Chức năng - Nhiệm vụCơ cấu tổ chức  Sơ đồ tổ chức Ban Chủ nhiệm khoa Các bộ môn  Lý luận - Điền kinh - Thể dục Thể thao cá nhân Thể thao tập thể Các tổ trực thuộc  Đào tạo - Công tác sinh viên Nghiên cứu khoa học - Đảm bảo chất lượng - HTQT Tổ chức Hành chính - Cơ sở vật chất Trung tâm Thể thaoSổ cấp chứng chỉDanh bạ điện thoạiĐóng góp ý kiến

Liên kết website

- Bộ GD&ĐT -Bộ Giáo dục & Đào tạoDiễn đàn Giáo dụcTrang tuyển sinhVăn bản pháp quy- Tin tức -Báo VNexpressBáo Dân tríTin tức 24hBáo Thanh niênBáo Tuổi trẻBáo Tiền phongBáo Lao độngBáo Giáo dục Thời đại

Thống kê truy cập

Lượt truy cập:348.664Hôm qua:22.879Hôm nay:3.819

Tin nổi bậtCông đoàn Khoa Giáo dục Thể chất và Trung tâm Thể thao dành giải Nhất Hội thi Tiếng hát Karaoke 08:31 | 07/03/2024 41Chào mừng kỉ niệm 114 năm ngày Quốc tế Phụ nữ (08/03/1910 - 08/03/2024). Công đoàn Cơ quan Đại học Đà Nẵng đã tổ chức "Hội thi Tiếng hát Karaoke" nhằm đẩy mạnh các phong trào hoạt động văn hóa, văn nghệ, tăng cường tinh thần đoàn kết gắn bó giữa các công đoàn viên, đơn vị.Chi tiết »

Thông báoTuyển sinh1 - Công đoàn Cơ quan Đại học Đà Nẵng tổ chức "Hội thi Tiếng hát Karaoke" năm 2024 08:18 | 05/03/2024 222 - Bổ sung chức năng in bảng điểm đối với sinh viên đã hoàn thành môn học Giáo dục thể chất 21:34 | 18/12/2023 9513 - Mời cán bộ, giảng viên và người học của ĐHĐN truy cập miễn phí các cơ sở dữ liệu quốc tế Science Direct và ProQuest Central 10:02 | 25/11/2023 1704 - Thành lập Đội tuyển Bóng rổ Sinh viên nam và nữ ĐHĐN tham gia thi đấu Giải Bóng rổ sinh viên toàn quốc năm 2023 09:28 | 21/10/2023 281Xem tất cả »1 - Thông báo tuyển sinh đại học chính quy theo phương thức xét học bạ cấp trung học phổ thông năm 2022 vào Trường Đại học Sư phạm, Đại học Đà Nẵng đợt bổ sung từ ngày 05/10/2022 đến ngày 15/10/2022 15:14 | 06/10/2022 3442 - Thông tin về thủ tục, hồ sơ xác nhận nhập học dành cho các thí sinh trúng tuyển theo phương thức xét kết quả thi THPT vào Đại học Đà Nẵng năm 2021 12:36 | 17/09/2021 1773 - Điểm chuẩn vào các trường đại học thành viên, đơn vị thuộc và trực thuộc ĐHĐN theo phương thức xét kết quả kỳ thi THPT 2021 12:34 | 17/09/2021 2344 - Hướng dẫn đăng ký dự thi năng khiếu ngành Giáo dục Thể chất năm 2019 10:21 | 11/04/2019 256Xem tất cả »

Tin tức hoạt độngĐại học Đà Nẵng tuyên dương, khen thưởng Đội tuyển Bóng rổ nam vô địch, Đội tuyển Bóng rổ nữ đạt hạng Ba tại Giải Bóng rổ sinh viên toàn quốc năm 2023 21:25 | 19/12/2023 481Chiều ngày 19/12, PGS.TS. Nguyễn Ngọc Vũ-Giám đốc Đại học Đà Nẵng (ĐHĐN) đã tham dự và tuyên dương, khen thưởng Đội tuyển Bóng rổ nam xuất sắc vô địch và Đội tuyển Bóng rổ nữ đạt hạng Ba tại Giải Bóng rổ sinh viên (SV) toàn quốc năm 2023 (NUC-2023).Khoa Giáo dục Thể chất - Đại học Đà Nẵng tổ chức Kỷ niệm 41 năm Ngày Nhà giáo Việt Nam (20/11/1982 - 20/11/2023) 19:06 | 22/11/2023 226Vào ngày 18/11/2023 Khoa Giáo dục Thể chất, Đại học Đà Nẵng đã tổ chức Kỷ niệm 41 năm Ngày Nhà giáo Việt Nam (20/11/1982 - 20/11/2023). PGS.TS. Lê Thành Bắc, Phó Giám đốc Đại học Đà Nẵng tới tham dự.Đại học Đà Nẵng10 dấu ấn, sự kiện nổi bật Đại học Đà Nẵng năm 2023 15:06 | 29/12/2023 201Bộ máy lãnh đạo Đại học Đà Nẵng và các trường, đơn vị thành viên được kiện toàn; Đề án phát triển Đại học Đà Nẵng thành Đại học Quốc gia được quan tâm đẩy mạnh;... là 2 trong 10 dấu ấn, sự kiện nổi bật Đại học Đà Nẵng năm 2023.Đội tuyển nam Đại học Đà Nẵng xuất sắc vô địch Giải Bóng rổ Sinh viên toàn quốc-2023 19:40 | 09/12/2023 186Chiều ngày 9/12, tại Nhà thi đấu Trường Đại học (ĐH) Sư phạm Hà Nội, trận Chung kết nam Giải Bóng rổ Sinh viên (SV) toàn quốc (NUC-2023) đã diễn ra hết sức sôi nổi, kịch tính với chất lượng chuyên môn cao. Kết quả chung cuộc với phần thắng xứng đáng đem lại danh hiệu Vô địch NUC-2023 cho Đội tuyển nam SV Đại học Đà Nẵng (ĐHĐN) vinh dự nhận Cúp và tiền thưởng của Ban Tổ chức (50 triệu đồng). 

Đăng nhập

Tên đăng nhập:

Mật khẩu:

Đăng nhập với vai trò

Sinh viên

Giảng viên, cán bộ

Quản trị viên

Đăng nhập

Tìm kiếm thông tin

Tìm kiếm

Bản quyền: Khoa Giáo dục Thể chấtĐịa chỉ: 62 Ngô Sĩ Liên, P. Hòa Khánh Bắc, Q. Liên Chiểu, TP. Đà Nẵng | Điện thoại: (+84.0236) 3 841 325

Design by EduSoft

GDTC Home

GDTC Home

"The best fun running club in New England"

GDTC HomeAbout UsCommunity RelationsPhoto Gallery

Boston Prep 16-Miler

Winter Fun Run Turkey Trot Run for Freedom

Mack's Apples Cross Country 5K Couch to 5K Kids Summer Fun Runs "The best fun running club in New England."

http://casinobest.org

Races & Events

Boston Prep 16 & 5 MilerTurkey TrotRun for FreedomMack's Apples 5KKids Summer Fun RunsCouch to 5KCouch to 5K Online RegistrationNH Grand Prix

Resources

Eldon's Friendly ReminderTrack WorkoutsUseful LinksNoteworthy NewsTips & TricksGDTC ApparelClub CalendarContact InformationRun For Freedom 10K Map

Timing & Results

GDTC races are professionally timed by New England Timing. The results are typically posted on My Race Results on the same day as the event. Please contact New England Timing directly with any questions.

2023 - 2024 Winter Fun Run Schedule

Read more: 2023 - 2024 Winter Fun Run Schedule

Why GDTC? Watch the Video

Why GDTC?

The Greater Derry Track Club is a non-profit organization formed in 1978 devoted to the promotion of a healthy lifestyle through running related activities, and to supporting the community through charitable endeavors.

Yearly Membership only $20 (or Less!)

Fun Runs, Races, Track Workouts, discounts at local and online stores and much more! Receive $5 credit towards your membership for each NHGP race you run for GDTC up to $20 credit. (Members– log in to see the list of discounts that your GDTC membership entitles you to!)

About the GDTC

Formed in 1978

Non-profit organization

Thousands of dollars donated to charity yearly 

Supporting the community

Promoting a healthy life-style

Great events!

Member Benefits:

Weekly “Gourmet Breakfast” Fun Runs (winter)

Sunday long runs

Coached track workouts (summer)

Couch to 5K programs

Discounts at local and online vendors

Eldon’s Friendly Reminder email

Team competition in the NH Grand Prix Series

Fun & competitive Mill Cities Relay Teams

Boston Marathon number lottery

College Scholarships

Annual dinner

NH Grand Prix Champions 2010, 2012, 2013 , 2014 , 2017 and 2022!

Search

Member Login

Username

Password

Remember Me

Log in

Affiliations

 

 

 

Join the GDTC!

The GDTC is a non-profit charitable organization formed in 1978 to promote running and support our community. We are proud to be known as "the best fun running club in New England." Join the GDTC Today!

Monthly Meetings

GDTC club meetings are held on the first Wednesday of the month. During the winter at 7:00 p.m. and during track season at 7:30 p.m. These meetings are open to everyone.

Sunday Long Runs

Club long runs are held every Sunday at 8:00AM (7:00AM Memorial Day – Labor Day) at The Coffee Factory 55 Crystal Ave, Hood Commons, Derry, NH. Map to Hood Plaza Coffee Factory.

 

Tuesday the 12th - Greater Derry Track Club, PO Box 402, Derry, NH 03038 - Designed by Obroll.com

CytoMed Therapeutics Limited (GDTC) Stock Price, News, Quote & History - Yahoo Finance

Med Therapeutics Limited (GDTC) Stock Price, News, Quote & History - Yahoo FinanceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...Yahoo FinanceSearchSkip to NavigationSkip to Main ContentSkip to Related ContentSign inMailSign in to view your mailWatchlistsMy PortfolioMarketsNewsVideosScreenersPersonal FinanceCryptoSectorsContact Us

Advertisement

U.S. markets closedS&P 5005,175.27+57.33(+1.12%)Dow 3039,005.49+235.83(+0.61%)Nasdaq16,265.64+246.36(+1.54%)Russell 20002,065.48-0.40(-0.02%)Crude Oil78.06+0.13(+0.17%)Gold2,164.20-24.40(-1.11%)CytoMed Therapeutics Limited (GDTC)NasdaqCM - NasdaqCM Real Time Price. Currency in USDFollow2.0700-0.0500 (-2.36%)At close: 03:59PM EDT SummaryChartConversationsStatisticsHistorical DataProfileFinancialsAnalysisOptionsHoldersSustainability1d5d1m6mYTD1y5yMaxFull screenTrade prices are not sourced from all marketsPrevious Close2.1200Open2.0829Bid2.0700 x 1800Ask2.3500 x 900Day's Range2.0700 - 2.120052 Week Range1.9200 - 9.2500Volume5,500Avg. Volume56,955Market Cap23.866MBeta (5Y Monthly)N/APE Ratio (TTM)N/AEPS (TTM)-0.2800Earnings DateN/AForward Dividend & YieldN/A (N/A)Ex-Dividend DateN/A1y Target EstN/AAllNewsPress ReleasesSEC FilingsGlobeNewswireCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairCytoMed diversifies into regenerative medicineSINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement (“RCA”) with Sengkang General HospitalAdasiabeutysecret66-Year-Old Lady with BABY face. This is what she does... GlobeNewswireMalaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyThe Company now has exclusive rights to a Malaysia, US and China patentSINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced today that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen recept

Advertisement

Advertisement

Advertisement

Data DisclaimerHelpSuggestionsTermsandPrivacy PolicyPrivacy DashboardAbout Our AdsSitemap© 2024 Yahoo. All rights reserved.

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

Skip to main content

S&P 500   5,175.27 (+1.12%) DOW   39,005.49 (+0.61%) QQQ   443.66 (+1.43%) AAPL   173.24 (+0.28%) MSFT   415.28 (+2.66%) META   499.75 (+3.34%) GOOGL   138.50 (+0.60%) AMZN   175.39 (+1.99%) TSLA   177.54 (-0.13%) NVDA   919.13 (+7.16%) NIO   6.19 (+1.48%) AMD   202.76 (+2.20%) BABA   76.06 (+1.60%) T   17.20 (-0.75%) F   12.11 (+0.00%) MU   97.42 (+3.08%) CGC   2.92 (-2.99%) GE   167.46 (+0.54%) DIS   112.46 (+0.13%) AMC   4.34 (-0.46%) PFE   28.01 (-1.27%) PYPL   60.02 (-0.10%) XOM   108.32 (-0.64%) S&P 500   5,175.27 (+1.12%) DOW   39,005.49 (+0.61%) QQQ   443.66 (+1.43%) AAPL   173.24 (+0.28%) MSFT   415.28 (+2.66%) META   499.75 (+3.34%) GOOGL   138.50 (+0.60%) AMZN   175.39 (+1.99%) TSLA   177.54 (-0.13%) NVDA   919.13 (+7.16%) NIO   6.19 (+1.48%) AMD   202.76 (+2.20%) BABA   76.06 (+1.60%) T   17.20 (-0.75%) F   12.11 (+0.00%) MU   97.42 (+3.08%) CGC   2.92 (-2.99%) GE   167.46 (+0.54%) DIS   112.46 (+0.13%) AMC   4.34 (-0.46%) PFE   28.01 (-1.27%) PYPL   60.02 (-0.10%) XOM   108.32 (-0.64%) S&P 500   5,175.27 (+1.12%) DOW   39,005.49 (+0.61%) QQQ   443.66 (+1.43%) AAPL   173.24 (+0.28%) MSFT   415.28 (+2.66%) META   499.75 (+3.34%) GOOGL   138.50 (+0.60%) AMZN   175.39 (+1.99%) TSLA   177.54 (-0.13%) NVDA   919.13 (+7.16%) NIO   6.19 (+1.48%) AMD   202.76 (+2.20%) BABA   76.06 (+1.60%) T   17.20 (-0.75%) F   12.11 (+0.00%) MU   97.42 (+3.08%) CGC   2.92 (-2.99%) GE   167.46 (+0.54%) DIS   112.46 (+0.13%) AMC   4.34 (-0.46%) PFE   28.01 (-1.27%) PYPL   60.02 (-0.10%) XOM   108.32 (-0.64%) S&P 500   5,175.27 (+1.12%) DOW   39,005.49 (+0.61%) QQQ   443.66 (+1.43%) AAPL   173.24 (+0.28%) MSFT   415.28 (+2.66%) META   499.75 (+3.34%) GOOGL   138.50 (+0.60%) AMZN   175.39 (+1.99%) TSLA   177.54 (-0.13%) NVDA   919.13 (+7.16%) NIO   6.19 (+1.48%) AMD   202.76 (+2.20%) BABA   76.06 (+1.60%) T   17.20 (-0.75%) F   12.11 (+0.00%) MU   97.42 (+3.08%) CGC   2.92 (-2.99%) GE   167.46 (+0.54%) DIS   112.46 (+0.13%) AMC   4.34 (-0.46%) PFE   28.01 (-1.27%) PYPL   60.02 (-0.10%) XOM   108.32 (-0.64%)

Free Trial Log in

Search

Find now

Research Tools

All Access Tools

My MarketBeat

My Portfolio

My Performance

My Insights

My Headlines

My Calendar

My Ratings

My Insider Trades

My Earnings

My SEC Filings

My Social

My Newsletter

My Portfolio Ideas

My Account

Calculators

Dividend Calculator

Dividend Yield Calculator

Market Cap Calculator

Options Profit Calculator

Stock Average Calculator

Stock Split Calculator

Stock Profit Calculator

Research Tools

Compare Stocks

Live News Feed

Momentum Alerts

Idea Engine

Stock Lists

Export Data (CSV)

Stock Screeners

Stock Screener

ETF Screener

Analyst Ratings Screener

Saved Ratings Searches

Dividend Screener

Earnings Screener

Insider Trades Screener

Top-Rated Analysts

Top-Rated Analysts

Top-Rated Brokerages

Trending Stocks

Trending MarketBeat Stocks

Trending Media Mentions

High Media Sentiment Stocks

Trending WallStreetBets Stocks

Premium Reports

All Reports

7 Election Stocks to Own 7 Magnificent Stocks in 2024

10 Best AI Stocks

Best Stocks for 2024 Report

Guide To High Short Interest Stocks

Elon Musk's Next Move

Next 7 Blockbuster Stocks

Stock Picks from Top Analysts

Financial Calendars

Calendars and Market Data

Analyst Ratings

U.S. Ratings

U.K. Ratings

Canadian Ratings

Stock Ratings by Issuer

Stock Ratings Screener

Top-Rated Stocks

Lowest-Rated Stocks

Top-Rated Analysts

Top-Rated Brokerages

Most-Upgraded Stocks

Most-Downgraded Stocks

Free Ratings Newsletter

Congressional Data

Recent Trades

Most Bought Stocks

Most Sold Stocks

Members of Congress

Corporate Events

Corporate Buybacks

Economic Reports

Initial Public Offerings (IPOs)

Secondary Public Offerings

IPO Lockup Expirations

IPO Quiet Period Expirations

SEC Filings

13F Filings

Top 13F Buys

Top 13F Sells

Stock Splits

Dividends

Today's Announcements

Ex-Dividend Calendar

Dividend Increases

Dividend Cuts

Dividend Kings

Dividend Achievers

Dividend Aristocrats

Best Dividend Stocks

Cheap Dividend Stocks

High-Yield Dividend Stocks

Monthly Dividend Stocks

Dividend Capture Stocks

Top-Rated Dividend Stocks

Dividend Screener

Dividend Investing Guide

Free Dividend Newsletter

Earnings

Today's Announcements

Tomorrow's Announcements

Next Week's Announcements

Upcoming Earnings Calls

Earnings Call Transcripts

Earnings Beats & Misses

Earnings Guidance

Earnings News

Earnings Screener

Insider Trades

Today's Insider Trades

CEO Purchases/Sales

CFO Purchases/Sales

Top Insider Buying Stocks

Top Insider Selling Stocks

Insider Trades Screener

Insider Trades Newsletter

Market Holidays

U.S. Market Holidays

Canadian Market Holidays

U.K. Market Holidays

Australian Market Holidays

Market Data

Market Data and Calendars

Commodities

Cryptocurrencies

All Cryptocurrencies

Cryptocurrency Headlines

Cryptocurrency Newsletter

Crypto Heatmap

Currencies

Gainers & Decliners

Percentage Gainers

Percentage Decliners

Breakout Stocks

Gap Up Stocks

Gap Down Stocks

High & Low PE

High PE Stocks

Low PE Stocks

High PE Growth Stocks

Low PE Growth Stocks

Highs & Lows

52-Week Highs

52-Week Lows

High & Low Beta Stocks

High Beta Stocks

Low Beta Stocks

Negative Beta Stocks

Indices

DOW 30

FTSE 100

NASDAQ Composite

S&P 500

S&P TSX

Low Priced Stocks

Stocks Under $0.50

Stocks Under $1

Stocks Under $2

Stocks Under $5

Stocks Under $10

Stocks Under $20

Stocks Under $30

Stocks Under $50

Stocks On Sale

Most Active

Most Active Stocks

Most Volatile Stocks

Unusual Trading Volume

Trading Halts

Options

Unusual Call Volume

Unusual Put Volume

Penny Stocks

Most Active Penny Stocks

Most Popular Penny Stocks

Top Penny Stocks Today

Sector Performance

U.S. Sector Performance

Canadian Sector Performance

U.K. Sector Performance

Cryptocurrency Performance

Short Interest

Largest Short Positions

Short Interest Increases

Short Interest Decreases

Stocks to Short

Stock Lists

All Stock Lists

Stocks by Interest

5G Stocks

Blue Chip Stocks

Biotech Stocks

Election Stocks

FAANG Stocks

Gold Stocks

Large Cap Stocks

Lumber Stocks

Marijuana Stocks

Oil Stocks

REITs

Russell 2000 Stocks

Small Cap Stocks

SPACs

Travel Stocks

Water Stocks

Warren Buffett Stocks

Stocks by Exchange

NYSE Stocks

NASDAQ Stocks

OTCMKTS Stocks

TSX Stocks

TSXV Stocks

LSE Stocks

Technical Indicators

Death Cross Stocks

Golden Cross Stocks

RSI Overbought Stocks

RSI Oversold Stocks

Stocks by Sector

Automotive Stocks

Aerospace Stocks

Basic Materials Stocks

Business Services Stocks

Consumer Discretionary Stocks

Consumer Staples Stocks

Construction Stocks

Energy Stocks

Finance Stocks

Industrial Stocks

Manufacturing Stocks

Medical Stocks

Real Estate Stocks

Retail Stocks

Technology Stocks

Transportation Stocks

Utilities Stocks

Stock Comparisons

Airline Stocks

Artificial Intelligence Stocks

Automotive Stocks

Bank Stocks

Bitcoin Stocks

Defense Stocks

EV Charging Stocks

Fertilizer Stocks

Growth Stocks

Lithium Stocks

Magnificent Seven Stocks

Marijuana Stocks

Meme Stocks

Pharmaceutical Stocks

Toy Stocks

WallStreetBets Stocks

Premium Stock Lists

Top MarketRank™ Stocks

Top ESG Stocks

Top-Rated Stocks

Top-Rated Dividend Stocks

Top-Rated Small-Cap Stocks

Top-Rated Tech Stocks

Lowest-Rated Stocks

Most-Upgraded Stocks

Most-Downgraded Stocks

Top Insider Buying Stocks

Top Insider Selling Stocks

Stocks to Short

Headlines

MarketBeat TVCrypto's Next Bull Run: Expert Insights with Robert RossCrypto's Next Bull Run: Expert Insights with Robert Ross3 Stocks That Members of Congress Can't Stop Buying3 Stocks That Members of Congress Can't Stop BuyingAeroVironment Stock Rockets To New HighAeroVironment Stock Rockets To New HighApple Scraps EV Plans: Here’s What’s Next, Lower PricesApple Scraps EV Plans: Here’s What’s Next, Lower PricesFeatured ArticlesAmbarella's Stock Turning Point: AI Set to Propel Growth in 2024ON Holdings Stock Price Tumbles: Is Now The Time to Buy?GameStop Stock Is Giving Investors a Familiar Feeling, But Why?Oracle Drives Next Era of AI Advancement: Stock Skyrockets by 15%Active Rebound: 2 Discrete Semiconductor Stocks Making MovesNike Stock Is Where You Can Find Growth Opportunity Reddit IPO: Analyzing Upvotes, Downvotes, and Financial PotentialKroger Stock: Anticipating New Highs as Promising Uptrend ResumesIs Hewlett Packard Enterprises Still a Cheap AI Server Play?Samsara's Surging Momentum Following Earnings BeatUnbearably Good Investment: A Build-A-Bear Stock AnalysisMore Featured Articles

News

Premium Articles

Real-Time News Feed

Economic News

Market News

Stock News

Inflation News

Political News

Dividends News

Earnings News

Instant News Alerts

All Headlines

Investing Slideshows

Learn

Featured Topic: Options Trading

Using Options for 1-for-2 Risk/Reward Ratio on UiPath EarningsHow to Use Options Collars to Hedge Your Stock GainsHow to Use Credit Spreads to Make Income from Optionsbluebird bio: How to play LEAPS options for growth and income How to Use Iron Condors to Collect Income from Stock OptionsHow to use options calendar spreads to generate weekly income

Learn

Read investment guides, how-to articles, and explainers.

Stock Ideas

Looking for ideas for stocks to invest in? These stocks are poised to move.

Financial Terms

Learn the language of investment with our glossary of over 200 financial terms.

Help

View our library of help videos to learn how to use the tools on the MarketBeat website.

NASDAQ:GDTC

CytoMed Therapeutics (GDTC) Stock Price, News & Analysis

$2.07 0.00 (0.00%) (As of 03:59 PM ET)

Add

Compare

Share Share

Today's Range$2.07▼$2.1350-Day Range$2.00▼$4.5452-Week Range$1.92▼$9.25Volume5,500 shsAverage Volume42,244 shsMarket Capitalization$22.65 millionP/E RatioN/ADividend YieldN/APrice Target$5.00

Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media

Get CytoMed Therapeutics alerts:

Email Address

About CytoMed Therapeutics Stock (NASDAQ:GDTC)CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.Read More

GDTC Stock Price History

View Price History Chart DataSkip Price History Chart

30 days | 90 days | 365 days | Advanced Chart

GDTC Stock News HeadlinesMarch 9, 2024 | americanbankingnews.comLongeveron (NASDAQ:LGVN) vs. CytoMed Therapeutics (NASDAQ:GDTC) Financial SurveyMarch 4, 2024 | globenewswire.comCytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and RepairMarch 12, 2024 | Stansberry Research (Ad)How to profit from the new boom in goldGold just passed $2,000/oz and is set for a new bull run in 2024. Now a renowned precious metals expert is sharing his No. 1 way to play it for just $5. August 15, 2023 | finance.yahoo.comCytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo PersistencyAugust 8, 2023 | investing.comCytoMed Therapeutics Ltd (GDTC)August 8, 2023 | finance.yahoo.comInsiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51mAugust 8, 2023 | finance.yahoo.comCytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell TechnologyAugust 8, 2023 | finance.yahoo.comChinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell TechnologyMarch 12, 2024 | The Oxford Club (Ad)Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big MoveHe started from nothing and became a multimillionaire...He's now one of the most sought-after trading experts...Yet he operates 858 miles from Wall Street.And now, he's revealing his #1 favorite strategy that targets MASSIVE weekly profits with just one stock ticker.July 11, 2023 | investorplace.comWhy Is CytoMed Therapeutics (GDTC) Stock Up 157% Today?See More Headlines

Receive GDTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytoMed Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Email Address

Company Calendar Today3/12/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GDTC CUSIPN/A CIK1873093 Webw2.cytomed.sg Phone65-6250-7738FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+137.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio36.40 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares10,940,000Free FloatN/AMarket Cap$23.08 million OptionableNot Optionable BetaN/A

7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report

Key ExecutivesMr. Chee Kong Choo (Age 66)Executive Chairman Comp: $5.45kDr. Wee Kiat Tan Ph.D. (Age 37)COO & Director Comp: $67.44kDr. Jieming Zeng (Age 51)Chief Scientific & Medical Officer and Director Comp: $78.48kDr. Tien Wee Luk (Age 38)Chief Clinical Officer & Director Ms. Yvonne Goh (Age 34)Chief Financial Officer Ms. Yoong Ying Tan (Age 35)Chief Corporate Officer More ExecutivesKey CompetitorsBullfrog AINASDAQ:BFRGForte BiosciencesNASDAQ:FBRXLisata TherapeuticsNASDAQ:LSTAOrgenesisNASDAQ:ORGSSol-Gel TechnologiesNASDAQ:SLGLView All Competitors

GDTC Stock Analysis - Frequently Asked Questions

Should I buy or sell CytoMed Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoMed Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GDTC shares. View GDTC analyst ratings or view top-rated stocks.

What is CytoMed Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for CytoMed Therapeutics' stock. Their GDTC share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 141.5% from the stock's current price. View analysts price targets for GDTC or view top-rated stocks among Wall Street analysts.

How have GDTC shares performed in 2024?

CytoMed Therapeutics' stock was trading at $4.90 at the beginning of the year. Since then, GDTC shares have decreased by 57.8% and is now trading at $2.07. View the best growth stocks for 2024 here.

Are investors shorting CytoMed Therapeutics?

CytoMed Therapeutics saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 19,300 shares, a decrease of 15.7% from the February 14th total of 22,900 shares. Based on an average daily volume of 53,300 shares, the short-interest ratio is currently 0.4 days. Currently, 0.5% of the company's stock are sold short. View CytoMed Therapeutics' Short Interest.

When is CytoMed Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our GDTC earnings forecast.

When did CytoMed Therapeutics IPO?

(GDTC) raised $10 million in an initial public offering (IPO) on Friday, April 14th 2023. The company issued 2,412,369 shares at a price of $4.00 per share.

How do I buy shares of CytoMed Therapeutics?

Shares of GDTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here.

This page (NASDAQ:GDTC) was last updated on 3/12/2024 by MarketBeat.com Staff

Adding

Choose a watchlist:

Watchlist

Cancel

Adding

You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

Cancel

Adding

CytoMed Therapeutics Limited

Please log in to your account or sign up in order to add this asset to your watchlist.

Cancel

Log In and Add

Get 30 Days of MarketBeat All Access Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Best-in-Class Portfolio Monitoring

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Stock Ideas and Recommendations

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Advanced Stock Screeners and Research Tools

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies.

Real-time analyst ratings, insider transactions, earnings data, and more.

Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

Sign In

Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

or

Sign in with Facebook

Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

or

Sign in with Facebook

Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

As Featured By:

Empowering Individual Investors

345 N Reid Place, Suite 620, Sioux Falls, SD 57103

contact@marketbeat.com

(844) 978-6257

Twitter

Facebook

YouTube

LinkedIn

About MarketBeat

About

Editorial Guidelines

Authors

Press Room

Careers

Contact

FAQ

Help

MarketBeat Products

Compare Products

MarketBeat All Access

Customer Reviews

MarketBeat Daily Ratings

MarketBeat Daily Canada

MarketBeat CryptoBeat

MarketBeat Mobile App

Popular Tools

Stock Lists

Compare Stocks

Dividend Calculator

My MarketBeat

Stock Screener

Financial Calendars

Analyst Ratings

Dividends

Earnings

Insider Trades

Stock Market Holidays

Terms & Info

Advertising

Accessibility Statement

Do Not Sell My Information

Privacy Policy

RSS Feeds

Terms of Service

Sitemap

© MarketBeat Media, LLC® 2010-2024. All rights reserved.

© 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.

My Account -

My MarketBeat

My Newsletter

My Alerts

My Subscriptions

My Account Settings

My Payment Settings

Log Out

×

Facebook

Facebook

CytoMed Therapeutics (Nasdaq:GDTC) - Stock Price, News & Analysis - Simply Wall St

CytoMed Therapeutics (Nasdaq:GDTC) - Stock Price, News & Analysis - Simply Wall St

DashboardMarketsDiscoverWatchlistPortfoliosScreenerStocks/Pharmaceuticals & BiotechCytoMed Therapeutics NasdaqCM:GDTC Stock ReportLast PriceUS$2.07Market CapUS$23.8m7D-7.5%1Yn/aUpdated11 Mar, 2024DataCompany Financials + 1 AnalystCytoMed Therapeutics LimitedNasdaqCM:GDTC Stock ReportMarket Cap: US$23.8mAdd to watchlistCompany Overview1Valuation2Future Growth3Past Performance4Financial Health5Dividend6Management7OwnershipOther InformationGDTC Stock OverviewCytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore.About the companyGDTC fundamental analysisSnowflake ScoreValuation0/6Future Growth1/6Past Performance0/6Financial Health5/6Dividends0/6RewardsRevenue is forecast to grow 8.95% per yearRisk AnalysisMakes less than USD$1m in revenue (SGD574K)Volatile share price over the past 3 monthsCurrently unprofitable and not forecast to become profitable over the next 3 yearsDoes not have a meaningful market cap ($24M)See All Risk ChecksCytoMed Therapeutics Limited CompetitorsARCA biopharmaNasdaqCM:ABIOUS$23.8mGalectoNasdaqGS:GLTOUS$23.6mLumos PharmaNasdaqGM:LUMOUS$24.7mDermTechNasdaqCM:DMTKUS$23.2mPrice History & PerformanceSummary of all time highs, changes and price drops for CytoMed TherapeuticsHistorical stock pricesCurrent Share PriceUS$2.0752 Week HighUS$9.2552 Week LowUS$1.92Beta01 Month Change-15.51%3 Month Change-40.66%1 Year Changen/a3 Year Changen/a5 Year Changen/aChange since IPO-48.25%Recent News & UpdatesNew minor risk - Financial data availability Nov 17New major risk - Share price stability Jul 13Executive Chairman recently bought US$750k worth of stock Apr 23See more updatesRecent updatesNew minor risk - Financial data availability Nov 17New major risk - Share price stability Jul 13Executive Chairman recently bought US$750k worth of stock Apr 23Shareholder ReturnsGDTCUS BiotechsUS Market7D-7.5%-0.8%-0.3%1Yn/a16.0%31.0%See full shareholder returnsReturn vs Industry: Insufficient data to determine how GDTC performed against the US Biotechs industry.Return vs Market: Insufficient data to determine how GDTC performed against the US Market.Price VolatilityIs GDTC's price volatile compared to industry and market?GDTC volatilityGDTC Average Weekly Movement15.9%Biotechs Industry Average Movement11.9%Market Average Movement6.2%10% most volatile stocks in US Market17.0%10% least volatile stocks in US Market3.1%Stable Share Price: GDTC's share price has been volatile over the past 3 months.Volatility Over Time: GDTC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.About the CompanyFoundedEmployeesCEOWebsite2018n/an/ahttps://w2.cytomed.sgCytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers.Show moreCytoMed Therapeutics Limited Fundamentals SummaryHow do CytoMed Therapeutics's earnings and revenue compare to its market cap?GDTC fundamental statisticsMarket capUS$23.75mEarnings (TTM)-US$3.23mRevenue (TTM)US$431.00k55.4xP/S Ratio-7.4xP/E RatioIs GDTC overvalued?See Fair Value and valuation analysisEarnings & RevenueKey profitability statistics from the latest earnings report (TTM)GDTC income statement (TTM)RevenueS$573.59kCost of RevenueS$11.09kGross ProfitS$562.50kOther ExpensesS$4.86mEarnings-S$4.29mLast Reported EarningsJun 30, 2023Next Earnings Daten/aEarnings per share (EPS)-0.37Gross Margin98.07%Net Profit Margin-748.62%Debt/Equity Ratio3.5%How did GDTC perform over the long term?See historical performance and comparisonView ValuationSimply Wall St™Simply Wall Street Pty LtdLevel 7, 320 Pitt Street, SydneyPopular MarketsUSAUUKINCAZAAbout UsCareersPlansLoginHelp CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseFinancial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by ClearbitSimply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.